Dr. Choueiri on the Research With Immunotherapy in RCC

Dr Choueiri on Lessons Learned from the TiNivo-2 Study in Metastatic RCCПодробнее

Drs. Choueiri, Pal, & Zand talk the lastest in #RCC from #ASCO22 - https://bit.ly/38CqllcПодробнее

Introducing immunotherapy again in RCC, adds any benefit? - CONTACT-03 #oncology #cancer #2023Подробнее

Dr. Choueiri on the Next Generation of Trials in RCCПодробнее

Dr. Choueiri on Frontline Trials of Immunotherapy in RCCПодробнее

Dr. Choueiri Discusses Immunotherapy in RCCПодробнее

Dr. Choueiri on the Subgroup Analysis of the JAVELIN Renal 101 Trial in RCCПодробнее

Watch Drs. Choueiri, McDermott, and Tannir, discuss the latest in RCC: https://bit.ly/3n3X59mПодробнее

Renal Cell Carcinoma | Cases from the Community: Investigators Discuss Available Research Guiding...Подробнее

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее

Dr. Choueiri on Ongoing Trials of Immunotherapy in RCCПодробнее

Dr. Choueiri Discusses Checkpoint Inhibitors in RCCПодробнее

Dr. Choueiri on Using Immunotherapy to Treat RCCПодробнее

Dr. Choueiri on Biomarkers in RCCПодробнее

Dr Toni Choueiri provides an update on kidney cancer management strategiesПодробнее

Dr. Choueiri on the Biology of the CABOSUN Trial for RCCПодробнее

Dr. Choueiri on the Impact of the JAVELIN Renal 101 Findings in RCCПодробнее

Dr. Choueiri on Trials Investigating Combination Regimens for RCCПодробнее

Dr. Choueiri on Synergy Between Immunotherapy and VEGF Inhibitors in RCCПодробнее